• Rejoni

  Participated · Series C · Jun 2026

  Rejoni is focused on developing and commercializing gynecological products built on proprietary biomaterials, with its lead investigational product the Juveena Hydrogel System. Juveena is designed to reduce the incidence and severity of intrauterine adhesions by placing a temporary hydrogel spacer in the uterine cavity using a proprietary transcervical catheter. The product is investigational and pending U.S. FDA approval and is not available for sale. Rejoni is clinical-stage and plans to scale manufacturing, supply operations, and market-access and physician/patient engagement in preparation for commercial launch. The company was founded in June 2020 in Bedford, MA; Amar Sawhney is founder and chairman and John Nealon is CEO. The recent $25 million financing will support these commercialization and regulatory preparations.

• Cypher AI

  Participated · Seed · May 2026

  Cypher AI is developing an operating-layer service that replaces fragmented, manual systems by unifying experiment design, execution, analysis, and vendor coordination in a single platform. The company works with biotech, pharma, and research organizations to accelerate discovery and innovation across the life sciences. Founded in 2025 by Yaoyu Yang and based in Cambridge, MA, Cypher AI recently closed a $2M Seed round to fund expansion. The company plans to use the proceeds to expand operations and further its development efforts. Early institutional investors in the seed include MaC Venture Capital, Epsilon Ventures, Connecticut Innovations, Sparta Group, and LiquidMetal Ventures. No revenue or user metrics are disclosed in the article.

• Stoke Space

  Participated · Series D · Oct 2025

  Stoke Space is developing Nova, a medium-class launch vehicle whose booster and upper stage are both designed for rapid reusability. Nova is engineered to deliver up to 3,000 kilograms to low Earth orbit while also allowing the upper stage to return payloads from orbit. The company is constructing launch infrastructure at Cape Canaveral Space Force Station’s Launch Complex 14 and expects the site to be finished by early 2026. Proceeds from recent financings are earmarked for ramping Nova production and accelerating additional elements of the firm’s product roadmap. Led by chief executive and co-founder Andy Lapsa, Stoke Space is working with urgency to bring Nova to market, though a first-launch date has not been announced. Including its latest capital infusion, the company has raised approximately $1.34 billion to date.

• Zolve

  Participated · Series B · Mar 2025

  Zolve offers banking and credit products to high‑skilled global citizens relocating to the U.S., using applicants' home‑country credit history to underwrite accounts on day one. The product set today includes checking accounts and credit cards, with plans to introduce loans starting with auto loans and later expanding to personal and education loans. The startup has amassed 750,000 customers since launch and has processed over $1.2 billion in transactions to date. Zolve reported $25 million in net revenue last year. The company aims to expand geographically, planning to enter Canada by July or August and the UK and Australia the following year. Longer term, it intends to build a connected financial network to serve users moving between Western and Asian markets. Zolve offers banking and credit products for immigrants, including the Zolve Debit Card, Zolve Credit Card and Zolve Azpire Credit Card, with accounts issued by Community Federal Savings Bank. The platform has attracted around 500,000 users since its inception and has facilitated more than $600M in transactions. Led by founder Raghunandan G, the company positions itself to expand its financial services internationally. Zolve plans to use new financing to grow across the UK, Canada and Australia. The cards and accounts are issued and offered by Community Federal Savings Bank, Member FDIC. The company previously raised $15M in a seed round and a subsequent $40M raise in October 2021. Zolve is a Bangalore-headquartered neobanking startup focused on helping immigrants gain access to U.S. financial services. Its core product is a credit card, complemented by a local bank account and debit card, with Zolve underwriting risk so partner banks can offer services without security deposits. The startup rolled out its credit card to 2,000 customers and has a waiting list exceeding 70,000, with customers widely using the product and paying on time. Customers have deposited about $2 million into Zolve accounts and are often using them as primary bank accounts. The company has grown headcount from five earlier this year to roughly 100 and plans to hire 150 more people. Zolve plans to expand offerings to immigrants from several additional countries early next year. Zolve is a neobanking platform aimed at individuals moving from India to the U.S. (and vice versa) that works with banks in both countries to provide seamless access to financial products. The startup underwrites the risk for partner banks, enabling customers to open accounts and obtain services as if they were banking with a national institution. Beyond basic banking, Zolve lets customers in India buy U.S.-listed shares and purchase cryptocurrency from exchanges based in the U.S. or Europe. The company is headquartered in San Francisco and Bangalore and was founded by Raghunandan G, who previously started TaxiForSure. Zolve has amassed more than 5,000 customers and has revenue-sharing arrangements with its banking partners. Because it onboards customers in India while generating much of its revenue from U.S. partners, the company says it is already operating on a profitable model.

• Brixton Biosciences

  Participated · Series B · May 2024

  Brixton Biosciences is a clinical-stage life sciences company developing Neural Ice, an injectable, drug-free pain management technology intended to provide long-lasting relief from chronic and post-operative pain. The company is refining Neural Ice and intends to accelerate its clinical application, expanding development beyond its initial study focused on chronic knee pain. Neural Ice is positioned as a non-pharmacological alternative aimed at reducing reliance on opioids and addressing aspects of the opioid crisis. Brixton recently received first-year funding of a $2 million grant (R44AR084998) from the NIH HEAL Initiative to support its development work. The award is intended to enable further development and clinical advancement of Neural Ice across additional indications. Sameer Sabir, CEO and co-founder, characterized the grant as a significant step toward bringing safer, non-addictive pain options to a broad array of patients. Brixton Biosciences is a Cambridge, MA-based clinical-stage life sciences company spun out of Massachusetts General Brigham and led by CEO Sameer Sabir. Its lead therapeutic approach, Neural Ice™, is a single, safe, drug-free injectable designed to provide locally targeted, non-addictive, and comparatively long-lasting pain relief. The company plans to use new capital to initiate pivotal clinical studies in both chronic and acute pain indications. Specifically, Brixton will pursue two pivotal studies to treat knee pain associated with osteoarthritis and pain from knee replacement surgery. Management says the firm intends to expand the Neural Ice platform beyond the knee to multiple pain indications with an ultra-long acting injectable nerve block. The company recently added Dr. Michael Fishman as Chief Medical Officer and appointed Reggie Groves to its board to support clinical and commercial efforts.

No current team members are available.